Payment overview · 2025
General Payments
$62.84
4 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher C Cosgrove, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WILMINGTON, NC · NPI 1790717296
Verified facts
What the public records show
CMS Open Payments records show Christopher C Cosgrove, MD received $62.84 in general payments during 2025 across 4 reported records.
Hologic Sales and Service, LLC accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Wegovy.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $18.97 | 30.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.91 | 25.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.45 | 23.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.51 | 21.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $62.84 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Wegovy wegovy |
2025 | Wegovy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 857 | 213 |
| Amlodipine Besylate | Amlodipine Besylate | 820 | 213 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 695 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 687 | 154 |
| Losartan Potassium | Losartan Potassium | 614 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 509 | 136 |
| Metoprolol Succinate | Metoprolol Succinate | 434 | 115 |
| Gabapentin | Gabapentin | 425 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 415 | 108 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 389 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 356 | 73 |
| Metformin Hcl | Metformin Hcl | 325 | 82 |
| Omeprazole | Omeprazole | 283 | 68 |
| Potassium Chloride | Potassium Chloride | 232 | 57 |
| Lisinopril | Lisinopril | 224 | 50 |
| Trazodone Hcl | Trazodone Hcl | 220 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 65 |
| Sertraline Hcl | Sertraline Hcl | 207 | 41 |
| Celecoxib | Celecoxib | 200 | 42 |
| Simvastatin | Simvastatin | 191 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 171 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 37 |
| Alprazolam | Alprazolam | 163 | 30 |
| Furosemide | Furosemide | 163 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 44 |
| Lorazepam | Lorazepam | 146 | 38 |
| Donepezil Hcl | Donepezil Hcl | 142 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 31 |
| Montelukast Sodium | Montelukast Sodium | 129 | 39 |
| Eliquis | Apixaban | 123 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 26 |
| Prednisone | Prednisone | 115 | 74 |
| Paroxetine Hcl | Paroxetine Hcl | 111 | 25 |
| Ozempic | Semaglutide | 101 | 20 |
| Memantine Hcl | Memantine Hcl | 100 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 23 |
| Metformin Hcl Er | Metformin Hcl | 94 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 40 |
| Alendronate Sodium | Alendronate Sodium | 89 | 19 |
| Meloxicam | Meloxicam | 89 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 16 |
| Clonazepam | Clonazepam | 86 | 20 |
| Tramadol Hcl | Tramadol Hcl | 85 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 81 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 71 | 69 |
| Allopurinol | Allopurinol | 70 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 13 |
| Cefuroxime | Cefuroxime Axetil | 67 | 55 |
| Ezetimibe | Ezetimibe | 66 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 45 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 61 | 18 |
| Atenolol | Atenolol | 56 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 14 |
| Januvia | Sitagliptin Phosphate | 55 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Finasteride | Finasteride | 52 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 12 |
| Synthroid | Levothyroxine Sodium | 50 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | 11 |
| Topiramate | Topiramate | 49 | 12 |
| Baclofen | Baclofen | 48 | suppressed |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 21 |
| Glipizide | Glipizide | 45 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 11 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Carvedilol | Carvedilol | 42 | 12 |
| Valacyclovir | Valacyclovir Hcl | 42 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 12 |
| Xarelto | Rivaroxaban | 38 | 11 |
| Famotidine | Famotidine | 36 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 29 |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Diazepam | Diazepam | 23 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Mesalamine | Mesalamine | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 16 |
| Wegovy | Semaglutide | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Colchicine | Colchicine | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Restasis | Cyclosporine | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Paricalcitol | Paricalcitol | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Zetia | Ezetimibe | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $62.84 · 4 records | Hologic Sales and Service, LLC | APTIMA, OTEZLA, REPATHA, THINPREP 2000 PROCESSOR, VOQUEZNA, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Wegovy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error